NASDAQ:MEDP - Medpace Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $161.67
  • Forecasted Upside: -9.16 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$177.96
▲ +2.08 (1.18%)

This chart shows the closing price for MEDP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Medpace Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MEDP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MEDP

Analyst Price Target is $161.67
▼ -9.16% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Medpace in the last 3 months. The average price target is $161.67, with a high forecast of $181.00 and a low forecast of $124.00. The average price target represents a -9.16% upside from the last price of $177.96.

This chart shows the closing price for MEDP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Medpace. This rating has held steady since September 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/1/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/31/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/27/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/26/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/24/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/17/2021Credit Suisse GroupBoost Price TargetOutperform$178.00 ➝ $181.00Medium
2/17/2021TruistBoost Price Target$135.00 ➝ $180.00Low
2/16/2021Credit Suisse GroupBoost Price TargetOutperform$155.00 ➝ $178.00Low
10/2/2020TruistUpgradeHold ➝ Buy$124.00 ➝ $135.00Medium
7/29/2020SunTrust BanksBoost Price TargetHold$95.00 ➝ $124.00Medium
7/28/2020Credit Suisse GroupBoost Price TargetOutperform$92.00 ➝ $114.00High
6/8/2020Robert W. BairdUpgradeUnderperform ➝ Neutral$83.00High
5/13/2020Wolfe ResearchDowngradeOutperform ➝ Peer Perform$91.00High
4/30/2020SunTrust BanksUpgradeSell ➝ Hold$54.00 ➝ $85.00High
4/29/2020Credit Suisse GroupLower Price TargetOutperform$105.00 ➝ $92.00High
4/20/2020Robert W. BairdDowngradeNeutral ➝ Underperform$77.00Low
4/6/2020SunTrust BanksBoost Price TargetSell$46.00 ➝ $54.00High
3/23/2020Jefferies Financial GroupLower Price TargetHold$93.00 ➝ $75.00Medium
3/17/2020SunTrust BanksDowngradeHold ➝ Sell$100.00 ➝ $46.00High
2/26/2020SunTrust BanksSet Price Target$100.00Medium
2/25/2020CSFBBoost Price TargetOutperform$91.00 ➝ $99.00High
2/25/2020Credit Suisse GroupBoost Price TargetOutperform$91.00 ➝ $99.00High
1/27/2020SunTrust BanksDowngradeBuy ➝ Hold$85.00 ➝ $87.00Low
7/31/2019SunTrust BanksBoost Price TargetBuy$85.00Low
7/30/2019Credit Suisse GroupBoost Price TargetOutperform$65.00 ➝ $77.00High
4/30/2019Robert W. BairdBoost Price TargetNeutral ➝ Neutral$57.00 ➝ $62.00High
4/2/2019Wolfe ResearchInitiated CoverageOutperformHigh
10/31/2018SunTrust BanksUpgradeHold ➝ Buy$63.00High
9/17/2018SunTrust BanksInitiated CoverageHold ➝ Hold$63.00High
7/31/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$42.00 ➝ $49.00High
7/31/2018William BlairUpgradeMarket Perform ➝ OutperformHigh
4/20/2018Mitsubishi UFJ Financial GroupReiterated RatingNeutral$40.00Low
4/10/2018Robert W. BairdSet Price TargetHold$35.00High
3/1/2018Jefferies Financial GroupReiterated RatingHold$35.00Low
2/28/2018Wells Fargo & CompanyLower Price TargetMarket Perform ➝ Market Perform$38.00 ➝ $35.00Medium
2/27/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$41.00 ➝ $42.00High
11/1/2017Jefferies Financial GroupBoost Price TargetHold$34.00 ➝ $38.00N/A
11/1/2017William BlairDowngradeOutperform ➝ Market PerformN/A
10/31/2017Robert W. BairdBoost Price TargetNeutral$32.00 ➝ $35.00N/A
10/17/2017KeyCorpReiterated RatingHoldN/A
10/9/2017Robert W. BairdReiterated RatingHold$32.00N/A
9/29/2017Raymond JamesInitiated CoverageMkt Perform ➝ Market PerformLow
8/2/2017Jefferies Financial GroupReiterated RatingHold$30.00 ➝ $31.00Low
6/6/2017Credit Suisse GroupReiterated RatingOutperform$35.00 ➝ $36.00Low
5/3/2017Jefferies Financial GroupReiterated RatingHold$35.50 ➝ $25.50Low
5/3/2017Wells Fargo & CompanyDowngradeOutperform ➝ Market PerformHigh
4/21/2017Jefferies Financial GroupReiterated RatingHold$35.50Low
3/29/2017KeyCorpInitiated CoverageOverweight ➝ Overweight$34.00Medium
2/28/2017Jefferies Financial GroupReiterated RatingHold$35.50N/A
11/7/2016Jefferies Financial GroupReiterated RatingHold$34.00N/A
10/4/2016Jefferies Financial GroupReiterated RatingHoldN/A
9/6/2016William BlairReiterated RatingOutperformN/A
9/6/2016Wells Fargo & CompanyInitiated CoverageOutperformN/A
9/6/2016UBS GroupInitiated CoverageBuy$35.00N/A
9/6/2016Robert W. BairdInitiated CoverageNeutral$35.00N/A
9/6/2016Jefferies Financial GroupInitiated CoverageHold ➝ Hold$32.50 ➝ $32.50N/A
9/6/2016Credit Suisse GroupInitiated CoverageOutperform$35.00N/A
(Data available from 6/24/2016 forward)
Medpace logo
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Read More

Today's Range

Now: $177.96
Low: $175.66
High: $178.26

50 Day Range

MA: $171.84
Low: $158.62
High: $194.30

52 Week Range

Now: $177.96
Low: $85.22
High: $196.12

Volume

138,181 shs

Average Volume

197,774 shs

Market Capitalization

$6.40 billion

P/E Ratio

42.17

Dividend Yield

N/A

Beta

1.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Medpace?

The following Wall Street research analysts have issued stock ratings on Medpace in the last year: Credit Suisse Group AG, SunTrust Banks, Inc., Truist, and Zacks Investment Research.
View the latest analyst ratings for MEDP.

What is the current price target for Medpace?

3 Wall Street analysts have set twelve-month price targets for Medpace in the last year. Their average twelve-month price target is $161.67, suggesting a possible downside of 8.0%. Credit Suisse Group AG has the highest price target set, predicting MEDP will reach $181.00 in the next twelve months. SunTrust Banks, Inc. has the lowest price target set, forecasting a price of $124.00 for Medpace in the next year.
View the latest price targets for MEDP.

What is the current consensus analyst rating for Medpace?

Medpace currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MEDP will outperform the market and that investors should add to their positions of Medpace.
View the latest ratings for MEDP.

What other companies compete with Medpace?

How do I contact Medpace's investor relations team?

Medpace's physical mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company's listed phone number is 513-579-9911 and its investor relations email address is [email protected] The official website for Medpace is www.medpace.com.